Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07286032 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia
A Phase 3 study, sponsored by Jiangsu HengRui Medicine Co..
- Recruiting
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
NCT07286032: Recruiting Phase 3 study, sponsored by Jiangsu HengRui Medicine Co..
NCT07286032 is a Phase 3 study that is actively recruiting participants, run by Jiangsu HengRui Medicine Co.. The registered enrollment target is 150 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07286032, a Phase 3 study, is actively recruiting participants, sponsored by Jiangsu HengRui Medicine Co..
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
Study Summary
The study is being conducted to evaluate the efficacy, and safety of of Hetrombopag Olamine Tablets Vs Placebo in Patients with Chemotherapy-Induced Thrombocytopenia.
Interventions
- DRUG Hetrombopag Olamine
- DRUG Hetrombopag Olamine ；Hetrombopag Olamine Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2026-04-16 |
| Est. Completion | 2029-06 |
| Phase | Phase 3 |
What NCT07286032 shows while recruiting
NCT07286032 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 2 interventions - of which Hetrombopag Olamine is the first listed.
NCT07286032 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07286032 about?
NCT07286032 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia". The study is being conducted to evaluate the efficacy, and safety of of Hetrombopag Olamine Tablets Vs Placebo in Patients with Chemotherapy-Induced Thrombocytopenia.
What is the current status of trial NCT07286032?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2026-04-16. Estimated completion is 2029-06.
What interventions are being tested in trial NCT07286032?
The interventions under investigation include: Hetrombopag Olamine (DRUG), Hetrombopag Olamine ；Hetrombopag Olamine Placebo (DRUG).
Who is sponsoring clinical trial NCT07286032?
This trial is sponsored by Jiangsu HengRui Medicine Co., which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07286032's enrollment target sits among peer trials
150 1519th of 2000 higher than 455 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI